ADMA Biologics vs Iovance Biotherapeutics
ADMA and IOVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADMA and IOVA compare
Iovance Biotherapeutics is the larger company, worth 1.2 times as much as ADMA Biologics ($3.5B against $3.0B).
Iovance Biotherapeutics grew revenue faster over the last twelve months (51.3% versus 6.3% for ADMA Biologics).
ADMA Biologics keeps more of each dollar of sales as profit, with a net margin of 35.1% compared with −58.2% at Iovance Biotherapeutics.
ADMA Biologics scores higher on the StockData Score (16 against 9 for Iovance Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADMA | IOVA |
|---|---|---|
| Size and price | ||
| Market cap | $3.0B | $3.5B |
| Share price | $13.24 | $7.63 |
| Change, 1 year | −17.4% | 188% |
| Change, 5 years | 765% | −59.5% |
| Beta (5Y) | 0.64 | 1.28 |
| Employees | 647 | 975 |
| StockData Score | ||
| Total score | 16 (better) | 9 |
| Valuation score | 5 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 4 (better) | 1 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 17.2× | – |
| P/S | 5.7× (better) | 9.1× |
| P/B | 6.8× | 4.3× (better) |
| EV/EBITDA | 12.2× | – |
| P/FCF | 22.3× | – |
| FCF yield | 4.5% (better) | −6.3% |
| Fair value | $21.15 | $4.53 |
| Margin of safety | 37.4% (better) | −68.3% |
| Growth | ||
| Revenue growth (TTM) | 6.3% | 51.3% (better) |
| Revenue growth, 5Y average | 64.6% | – |
| Net income growth (TTM) | −12.9% | – |
| EPS growth (TTM) | −9.4% | – |
| Profitability | ||
| Gross margin | 68.5% (better) | 53.2% |
| Operating margin | 46.5% (better) | −60.8% |
| Net margin | 35.1% (better) | −58.2% |
| FCF margin | 25.6% (better) | −57.0% |
| Return on equity | 41.9% (better) | −29.1% |
| Return on invested capital | 39.4% (better) | −43.4% |
| Financial health | ||
| Debt / equity | 0.45 (better) | 0.00 |
| Net debt / EBITDA | 0.29 | – |
| Interest coverage | 22.8× | – |
| Current ratio | 6.04 (better) | 5.20 |
| Altman Z-score | 8.58 (better) | 7.64 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | 6.4% (better) | −8.4% |
| Shareholder yield | 6.4% (better) | −8.4% |
| Ownership | ||
| Held by institutions | 91.8% | 63.3% |
| Held by insiders | 3.0% | 0.38% |
| Insider net buying, 12 months | −$2.5M | – |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 8.3% | 14.4% |
Go deeper
- ADMA stock overview
- ADMA income statement
- ADMA valuation and score
- IOVA stock overview
- IOVA income statement
- IOVA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.